Hansa has established a research and development collaboration with French Genenthon based on the candidate GNT-0003 which has recently entered the pivotal study stage. If approved, some 30-40% of patients are likely to develop NABs (antibody reactions), and this is where Hansa’s Imlifidase could open up for treatment of a larger patient group. We believe this research collaboration could evolve into a commercial partnership within 12 months, depending on the preclinical (safety) outcome of the combination study and the results from the recently completed stage of the GNT-0003 study.
LÄS MER
